Criteria Fulfill
Item
all patient must:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Follicular Lymphoma WHO tumor classification
Item
1. have had a histologically confirmed diagnosis of grade 1 or 2 fl, according to world health organization classification (harris et al. 1999), at the original time of diagnosis. pathology must be confirmed locally prior to enrollment at the investigational site.
boolean
C0024301 (UMLS CUI [1,1])
C1301142 (UMLS CUI [1,2])
Disease Ann Arbor lymphoma staging system
Item
2. have ann arbor stage iii or iv disease.
boolean
C0012634 (UMLS CUI [1,1])
C0432516 (UMLS CUI [1,2])
Chemotherapy naive | rituximab | Chemotherapy Quantity Completed | Recurrent disease
Item
3. must be chemo-naive or have relapsed disease after receiving only one prior chemotherapy regimen. the chemotherapy must have been completed at least 6 months prior to first dose of study treatment. relapse after one prior course of single-agent rituximab treatment (in the chemo-naive setting) is also allowed if completed at least 6 months prior to first dose of study treatment.
boolean
C0392920 (UMLS CUI [1,1])
C0919936 (UMLS CUI [1,2])
C0393022 (UMLS CUI [2])
C0392920 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0205197 (UMLS CUI [3,3])
C0277556 (UMLS CUI [4])
Therapeutic procedure Cytoreductive effect | Requirement Absent
Item
4. patients must not require cytoreductive therapy for at least 3 months from first dose of study treatment, in the opinion of the investigator.
boolean
C0087111 (UMLS CUI [1,1])
C0864494 (UMLS CUI [1,2])
C1514873 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Therapeutic radiology procedure Limited Completed | Therapeutic radiology procedure Whole-Pelvis Absent | Toxic effect Patient recovered | Alopecia Excluded | Lesion Tumor Progression | Measurable Disease
Item
5. previous radiation therapy is allowed, but should have been limited and must not have included whole pelvis radiation. patients must have recovered from the toxic effects of the treatment prior to study enrollment (except for alopecia). prior radiotherapy must be completed 30 days before study entry. lesions that have been irradiated cannot be included as sites of measurable disease unless clear tumor progression has been documented in these lesions since the end of radiation therapy.
boolean
C1522449 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])
C1522449 (UMLS CUI [2,1])
C3827467 (UMLS CUI [2,2])
C0332197 (UMLS CUI [2,3])
C0600688 (UMLS CUI [3,1])
C1115804 (UMLS CUI [3,2])
C0002170 (UMLS CUI [4,1])
C2828389 (UMLS CUI [4,2])
C0221198 (UMLS CUI [5,1])
C0178874 (UMLS CUI [5,2])
C1513041 (UMLS CUI [6])
Criteria Fulfill
Item
patients will be excluded from the study if they meet any of the following criteria:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Unable to swallow tablet
Item
1. are unable to swallow tablets.
boolean
C3839225 (UMLS CUI [1])
Carbamazepine Unable to discontinue | Phenobarbital Unable to discontinue | Phenytoin Unable to discontinue
Item
2. are unable to discontinue use of carbamazepine, phenobarbital, and phenytoin.
boolean
C0006949 (UMLS CUI [1,1])
C1548265 (UMLS CUI [1,2])
C0031412 (UMLS CUI [2,1])
C1548265 (UMLS CUI [2,2])
C0031507 (UMLS CUI [3,1])
C1548265 (UMLS CUI [3,2])
cancer treatment
Item
3. are receiving concurrent administration of any other antitumor therapy.
boolean
C0920425 (UMLS CUI [1])
Pregnancy | Breast Feeding
Item
4. are pregnant or breastfeeding.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Systemic disease Serious compromises Protocol Compliance | Bacterial Infections | Mycoses | Virus Diseases
Item
5. have a serious concomitant systemic disorder (including active bacterial, fungal, or viral infection) that, in the opinion of the investigator, would compromise the patient's ability to adhere to the protocol.
boolean
C0442893 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C2945640 (UMLS CUI [1,3])
C0525058 (UMLS CUI [1,4])
C0004623 (UMLS CUI [2])
C0026946 (UMLS CUI [3])
C0042769 (UMLS CUI [4])